Trial Profile
Safety and Tolerability of Multiple Ascending Doses of LY2140023 in Subjects With Schizophrenia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Pomaglumetad methionil (Primary) ; Aripiprazole
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Denovo Biopharma
- 09 Aug 2012 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.
- 27 Mar 2012 Planned end date changed from 1 Mar 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 01 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.